Keytruda Cancer Drug Exposes Global Divide as Patients Face High Costs and Counterfeit Risks
Updated
Updated · ICIJ.org · Apr 13
Keytruda Cancer Drug Exposes Global Divide as Patients Face High Costs and Counterfeit Risks
16 articles · Updated · ICIJ.org · Apr 13
An international investigation has revealed that Merck's cancer drug Keytruda, while lifesaving for some, remains unaffordable or inaccessible for many patients worldwide.
High prices, extensive patent protections, and opaque pricing systems have led to rationing, legal battles, and even counterfeit drug rackets in countries like India.
The situation highlights deep global health inequalities, as access to Keytruda often depends on geography, income, and the ability to navigate complex healthcare systems.
As patents extend to 2042, will cheaper Keytruda alternatives ever reach patients?
How will Merck's new at-home Keytruda injection dodge upcoming government price cuts?
Keytruda's R&D cost was 3% of revenue. Where did the other $158 billion go?
Without huge profits from drugs like Keytruda, would future cancer research come to a halt?
Why does this cancer drug cost $80,000 in Germany but $208,000 in the U.S.?
Is extending a drug's patent with a new version true innovation or just profit protection?
How Merck’s Patent Fortress Extends Keytruda Monopoly to 2042, Blocking Affordable Cancer Treatment Worldwide
Overview
Merck's extensive patent strategy has extended Keytruda's market exclusivity until 2042, causing huge price differences worldwide—$208,000 in the US versus $65,000 in South Africa. These high costs force many patients to crowdfund for treatment or face deadly delays, while doctors in poorer countries must ration the drug. The unaffordability also fuels a dangerous counterfeit market, with fake Keytruda causing treatment failures and eroding trust in healthcare. As Keytruda's patent expires in 2028, Indian companies are racing to develop biosimilars that could cut costs by up to 60%, but challenges remain. Global policy reforms and improved supply chains are essential to ensure fair access and combat counterfeits.